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Prospective surveillance for influenza was performed
during the 2002 Salt Lake City Winter Olympics.
Oseltamivir was administered to patients with influenzalike
illness and confirmed influenza, while their close contacts
were given oseltamivir prophylactically. Influenza A/B was
diagnosed in 36 of 188 patients, including 13 athletes.
Prompt management limited the spread of this outbreak. 
T
he Olympics are the quintessential organized sport
where elite international athletes live in close quarters
and compete in an intense environment. Upper respiratory
illnesses occur frequently (1), and influenzalike illnesses
(ILI) have been reported in previous Olympics (2–6).
Prospective surveillance was conducted for influenza, with
an emphasis on diagnosis, treatment, and prevention, dur-
ing the 2002 Winter Olympics/Paralympic Games.
The Study
This study was performed at the Olympic Village
Polyclinic during the 2002 Winter Olympiad in Salt Lake
City, Utah, USA, during February and March 2002.
Athletes and nonathletes with upper/lower respiratory
symptoms (with or without febrile/systemic illness) were
screened for influenza by various modalities. Viral test
results from the Polyclinic and public health reports of
influenza in the local community were reviewed daily.
Patients with ILI or confirmed influenza were offered treat-
ment with oseltamivir; close contacts were offered prophy-
laxis (detailed methods available from corresponding
author by email).
Atotal of 2,635 medical visits were recorded during the
Games; patients with any respiratory symptom represented
12%. Of these, 188 satisfied the symptom criteria for the
study (available from corresponding author) and were
screened for influenza (Table 1).  Influenza A was detect-
ed in 28 (15%) and influenza B in 8 (4%) patients (Table
2). Athletes comprised 36% of all influenza patients. Of
the influenza Aisolates, 8 were further analyzed and found
to be consistent with the A/Sydney/ 97(H3N2) strain (rep-
resented in the 2001–2002 vaccine).
Patients with confirmed influenza (Table 2) were more
likely to be male, have a temperature >37.8°C, and have a
history of cough or chills. No significant differences were
found in symptom duration or influenza vaccination status
among those with and without influenza. Athletes were
more likely to have a diagnosis of influenza A than other
pooled groups of nonathletes (odds ratio [OR] 3, 95% con-
fidence interval [CI] 1.1–7.5, p = 0.03).
Twenty-five of 188 patients who were screened by
direct fluorescent-antibody assay (DFA) for influenza were
positive. When the results were compared to viral culture
alone, sensitivity was 70%, specificity was 99%, positive
likelihood ratio was 54, and negative likelihood ratio was
0.3. Ten (6%) of the 160 who received a rapid influenza test
had positive results. The sensitivity of the rapid test for
diagnosing influenza (when compared to a confirmed diag-
nosis by viral culture, polymerase chain reaction, or DFA)
was 17%, while the specificity was 97%. The positive like-
lihood ratio and negative likelihood ratio were 5.2 and 0.9.
The conventional syndromic definition of ILI (fever
and either cough or sore throat) (7) had a low positive like-
lihood ratio of 2.7, negative likelihood ratio of 0.5, sensi-
tivity of 67%, and specificity of 78% in predicting
influenza. Overall, 23% of nonathletes and 18% of athletes
screened reported influenza vaccination. Of those with
confirmed influenza, vaccinees were likely to have lower
fevers, although the results were not significant.
Physicians prescribed oseltamivir for 60 (32%) of 188
patients screened for influenza. Of the medicated patients,
40 (67%) were treated for ILI within 48 hours of symptom
onset; influenza was confirmed in 21. Oseltamivir prophy-
laxis (for 5 days) was prescribed in 20 (33%) patients who
had a history of contact with influenza patients; 1 case of
influenza was confirmed in this group. All patients who
received oseltamivir tolerated the medication well.
Three distinct clusters of ILI were identified during the
Games. Cluster I consisted of 13 law enforcement personnel
who worked and lived in close proximity. In early February,
3 members came to the clinic 4 days apart with ILI, and
influenza A was diagnosed (2 cases by DFA, 1 by viral cul-
ture). Oseltamivir prophylaxis was promptly initiated in the
remaining 10 asymptomatic members; the oseltamivir was
well tolerated. No other cases of ILI were reported. The
group was able to discharge its duties in the village.
Cluster II consisted of 12 members of a national team
who had trained together at a common location 3 days
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they arrived, the index patient (unvaccinated for influenza)
came to the clinic with ILI of 24 hours’ duration and was
given oseltamivir. Upon confirmation of influenza A by
DFA, unvaccinated asymptomatic close contacts of the
patients were offered oseltamivir prophylaxis; 8 of 11
accepted. In the next 4 days, 3 vaccinated teammates who
had not received prophylaxis came to the clinic with ILI of
24 hours’ duration. Treatment was initiated because of
their close contact with the index patient. One patient was
subsequently found to have influenza A by DFA. No fur-
ther cases of ILI were reported. The team competed suc-
cessfully in the sport and won several medals.
Cluster III consisted of 8 participants of 1 sport (which
had 80 participants with common training venues) sought
treatment at the Polyclinic within 9 days with respiratory
symptoms (5 had ILI, 3 were afebrile). The 5 with ILI were
treated with oseltamivir. Of the 3 afebrile participants, 2
were provided prophylaxis based on their contact history
and symptoms. The third patient was not offered prophy-
laxis due to insufficient contact history. Influenza A was
confirmed in 5 patients. No reports of ILI or confirmed
influenza occurred among participants from this group
after treatment/prophylaxis was initiated.
Conclusions
This is the first systematic influenza study at any large
international sports gathering and demonstrates the
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vention strategy integrated a policy of empiric treatment
based on clinical data and viral testing with a public health
surveillance approach, including daily review of all viral
test results from the Polyclinic and reports of influenza in
the community. Potential clusters of influenza were
promptly identified, index patients were treated with
oseltamivir, and contacts were given oseltamivir prophy-
laxis.
We examined several methods of detecting influenza
from respiratory samples and found DFA testing to be the
most useful surveillance tool in this setting. The sensitivi-
ty of rapid testing was low. This observation is consistent
with the variability typically associated with rapid testing
regarding patient age, duration of symptoms, type of kit,
and timing of specimen acquisition (7–9). 
Alow rate of influenza immunization was noted among
participants. The World Health Organization and others
have suggested that vaccination is beneficial for athletes
(2,4,10–12). Although this study was not designed to
address the effectiveness of influenza vaccination, we sup-
port issuing a public health alert that encourages adminis-
tering influenza vaccine to all athletes and staff before a
large international event is staged.
Team physicians may not have reported all episodes of
ILI to the Polyclinic, though this scenario is unlikely, given
their frequent direct communication. Alternative strategies
for influenza control, such as mass vaccination (13), were
not examined in this study. Followup was not attempted
since patients often dispersed to various international des-
tinations after their events.
In summary, the surveillance and intervention strategy
used in this study may serve as a model for mobilizing
teams to provide health care to a large assembly of partic-
ipants. Initiating empiric treatment for influenza based on
clinical and epidemiologic data, combined with testing by
DFA (with subsequent confirmation by viral culture), may
be a prudent approach to influenza control in large gather-
ings. Close contacts of persons with positive DFA tests
would then be candidates for prophylaxis. Similar
approaches may enhance preparedness for public health
threats and emerging respiratory pathogens such as avian
influenza and agents of bioterrorism.
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